1134299

应用筛选条件

关键词:'1134299'

显示 1-6 共 6 条结果关于 "1134299" 范围论文

Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.

M Kjaer et al.

Acta oncologica (Stockholm, Sweden), 27(5), 583-589 (1988-01-01)

Thirteen cancer patients with moderate to severe chronic pain of malignant origin on treatment with Ketogan tablets were included in an open non-randomized cross-over study comparing the analgesic effect, side effects and serum concentrations of Ketogan tablets and mixture. The

Premedication for day-case surgery: double-blind comparison of ketobemidone + dimethylaminodiphenylbuten (A-29) and morphine + scopolamine.

J C Raeder et al.

Acta anaesthesiologica Scandinavica, 30(7), 502-506 (1986-10-01)

A double-blind comparison of the effect of Ketogan (ketobemidone and A-29, an anticholinergic and spasmolytic agent) and morphine + scopolamine as premedication was performed in 113 women admitted for abortion and in 114 women admitted for gynaecological dilatation and curettage.

Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.

P Anderson et al.

European journal of clinical pharmacology, 19(3), 217-223 (1981-02-01)

The pharmacokinetic constants and rectal bioavailability of the narcotic analgesic ketobemidone were determined in six male patients after surgery. Plasma concentrations were measured following intravenous administration of Ketogin 2 ml, containing ketobemidone chloride 10 mg, and a spasmolytic compound N,N-dimethyl-3,3-diphenyl-1-methylallylamine

Ketobemidone plus (RS)-3-dimethylamino-1,1-diphenylbut-1-ene (A29) is more potent at NMDA receptors than ketobemidone alone: evidence for A29 as a non-competitive NMDA receptor antagonist.

B Ebert et al.

Pharmacology & toxicology, 82(3), 157-160 (1998-04-29)

The opioid, ketobemidone, has previously been shown to be a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. In Denmark, ketobemidone is available in a formulation which contains ketobemidone and a spasmolytic compound, (RS)-3-dimethylamino-1,1-diphenylbut-1-ene, hydrochloride (A29), in a one to five ratio. Using

The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene.

K Kristensen et al.

Pharmacology & toxicology, 79(2), 103-104 (1996-08-01)

Histamine release from human basophils and isolated rat mast cells induced by ketobemidone, pethidine and the spasmolytic A29.

N Grosman

Acta pharmacologica et toxicologica, 50(1), 78-80 (1982-01-01)

1/1